Pharmacological inhibition of EGFR has shown to reduce high-fat diet-induced liver injury in mouse models of NAFLD (73, 74), suggesting that targeting EGFR signaling may prove to have therapeutic potential in human NASH. Here, EGFR is linked to metabolic dysfunction-associated steatotic liver disease.